PBYI - Puma Biotechnology Inc Stock Price, Fair Value and News

4.66USD-0.09 (-1.89%)Delayed as of 08 May 2024, 02:06 pm ET

Market Summary

USD4.66-0.09

Delayedas of 08 May 2024, 02:06 pm

-1.89%

PBYI Stock Price

View Fullscreen

PBYI RSI Chart

PBYI Valuation

Market Cap

229.1M

Price/Earnings (Trailing)

14.89

Price/Sales (Trailing)

1.01

EV/EBITDA

Price/Free Cashflow

6.47

PBYI Price/Sales (Trailing)

PBYI Profitability

Operating Margin

72.46%

EBT Margin

7.29%

Return on Equity

30.19%

Return on Assets

7.19%

Free Cashflow Yield

15.46%

PBYI Fundamentals

PBYI Revenue

Revenue (TTM)

226.6M

Rev. Growth (Yr)

-17.07%

Rev. Growth (Qtr)

-39.36%

PBYI Earnings

Earnings (TTM)

15.4M

Earnings Growth (Yr)

-442.61%

Earnings Growth (Qtr)

-139.13%

Breaking Down PBYI Revenue

52 Week Range

2.404.87

(Low)(High)

Last 7 days

-6.5%

Last 30 days

-16.2%

Last 90 days

-5.9%

Trailing 12 Months

48.1%

How does PBYI drawdown profile look like?

PBYI Financial Health

Current Ratio

1.46

Debt/Equity

1.07

Debt/Cashflow

0.65

PBYI Investor Care

Shares Dilution (1Y)

3.28%

Diluted EPS (TTM)

0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	226.6M	0	0	0
2023	235.1M	230.1M	229.1M	235.6M
2022	200.7M	206.9M	217.7M	228.0M
2021	272.1M	254.9M	250.4M	253.2M
2020	224.4M	241.1M	235.5M	225.1M
2019	283.5M	286.7M	280.4M	272.3M
2018	86.3M	145.0M	201.5M	251.0M
2017	0	0	0	27.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Puma Biotechnology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	auerbach alan h	acquired	-	-	6,577	president and ceo
Feb 12, 2024	hunt douglas m	acquired	-	-	37,894	see remarks
Feb 12, 2024	ludwig jeffrey jerome	acquired	-	-	27,067	chief commercial officer
Feb 12, 2024	wong alvin f	acquired	-	-	43,307	chief scientific officer
Feb 12, 2024	auerbach alan h	acquired	-	-	160,796	president and ceo
Feb 12, 2024	nougues maximo f	acquired	-	-	43,307	chief financial officer
Jan 03, 2024	nougues maximo f	sold	-70,347	4.4859	-15,682	chief financial officer
Jan 03, 2024	hunt douglas m	sold	-37,493	4.4859	-8,358	see remarks
Jan 03, 2024	wong alvin f	sold	-34,689	4.4859	-7,733	chief scientific officer
Jan 03, 2024	ludwig jeffrey jerome	sold	-58,119	4.4859	-12,956	chief commercial officer

Which funds bought or sold PBYI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SG Americas Securities, LLC	new	-	57,000	57,000	-%
May 06, 2024	Metis Global Partners, LLC	new	-	209,493	209,493	0.01%
May 06, 2024	LSV ASSET MANAGEMENT	reduced	-64.92	-214,000	161,000	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-28.49	-142,000	994,000	0.08%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	235	1,283	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Patriot Financial Group Insurance Agency, LLC	reduced	-66.67	-88,435	60,950	0.01%
Apr 30, 2024	GPS Wealth Strategies Group, LLC	unchanged	-	970	5,300	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	0.38	10,000	57,000	-%
Apr 26, 2024	JNBA Financial Advisors	sold off	-100	-18.00	-	-%

Are Funds Buying or Selling PBYI?

Are funds buying PBYI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PBYI

No. of Funds

Unveiling Puma Biotechnology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	frazier life sciences public fund, l.p.	2.7%	1,295,100	SC 13G
Feb 14, 2024	camber capital management lp	5.90%	2,013	SC 13G/A
Feb 13, 2024	vanguard group inc	7.99%	3,802,081	SC 13G/A
Feb 06, 2024	acorn bioventures, l.p.	2.6%	1,232,490	SC 13G/A
Jan 30, 2024	millennium management llc	6.0%	2,843,239	SC 13G/A
Sep 01, 2023	acorn bioventures, l.p.	2.4%	1,150,774	SC 13G
Feb 14, 2023	camber capital management lp	9.28%	2,013	SC 13G/A
Feb 09, 2023	vanguard group inc	7.86%	3,588,922	SC 13G/A
Feb 07, 2023	goldman sachs group inc	0.9%	396,136	SC 13G/A
Jan 19, 2023	millennium management llc	5.8%	2,676,913	SC 13G/A

Recent SEC filings of Puma Biotechnology Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 29, 2024	SC 13G	Major Ownership Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report

Peers (Alternatives to Puma Biotechnology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Puma Biotechnology Inc News

Latest updates

Puma Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-39.4%	44.00	72.00	56.00	55.00	53.00	66.00	57.00	60.00	46.00	55.00	46.00	53.00	98.00	53.00	51.00	71.00	51.00	63.00	56.00	54.00	99.00
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	12.00	30.00	11.00	10.00	9.00	9.00	10.00	9.00	9.00	8.00
Costs and Expenses	-19.7%	46.00	57.00	48.00	50.00	48.00	56.00	55.00	47.00	46.00	49.00	55.00	70.00	78.00	-	63.00	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	70.00	78.00	64.00	63.00	63.00	65.00	72.00	71.00	80.00	89.00
S&GA Expenses	7.8%	22.00	20.00	23.00	24.00	22.00	25.00	24.00	21.00	20.00	23.00	26.00	39.00	28.00	29.00	30.00	29.00	31.00	31.00	31.00	34.00	46.00
R&D Expenses	-	-	-	-	-	-	-	-	12.00	15.00	14.00	19.00	19.00	20.00	24.00	23.00	25.00	25.00	30.00	30.00	37.00	36.00
EBITDA Margin	-9.3%	0.18*	0.20*	0.13*	0.09*	0.12*	0.10*	0.14*	-0.06*	-0.13*	-0.02*	-0.09*	-0.03*	-	-	-	-	-	-	-	-	-
Interest Expenses	0.1%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00	4.00	3.00	3.00	3.00	4.00	4.00
Income Taxes	-59.0%	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Earnings Before Taxes	-135.9%	-4.59	13.00	6.00	2.00	2.00	-5.31	-0.29	9.00	-3.37	4.00	-44.63	-5.07	17.00	-14.79	-31.46	3.00	-16.93	-	-	-	-
EBT Margin	-24.2%	0.07*	0.10*	0.02*	-0.01*	0.02*	0.00*	0.05*	-0.17*	-0.24*	-0.11*	-0.19*	-0.14*	-	-	-	-	-	-	-	-	-
Net Income	-139.1%	-4.80	12.00	6.00	2.00	1.00	-5.61	-0.36	9.00	-3.40	4.00	-44.67	-5.11	17.00	-14.99	-31.46	3.00	-16.93	-11.20	-16.89	-37.42	-10.09
Net Income Margin	-25.9%	0.07*	0.09*	0.02*	-0.01*	0.02*	0.00*	0.04*	-0.17*	-0.24*	-0.11*	-0.19*	-0.14*	-	-	-	-	-	-	-	-	-
Free Cashflow	7.7%	11.00	10.00	11.00	3.00	3.00	8.00	17.00	-13.87	-26.89	-5.43	10.00	-0.10	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.1%	214	231	204	200	196	222	199	194	201	227	226	260	259	244	262	264	226	235	232	240	331
Current Assets	-8.4%	143	156	125	119	112	134	122	114	118	140	137	168	164	146	160	159	159	166	151	158	256
Cash Equivalents	-9.3%	77.00	85.00	82.00	60.00	61.00	76.00	78.00	53.00	64.00	63.00	64.00	90.00	96.00	85.00	90.00	91.00	83.00	60.00	59.00	27.00	49.00
Inventory	0.3%	7.00	7.00	6.00	8.00	4.00	5.00	5.00	7.00	7.00	7.00	7.00	8.00	8.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Net PPE	-11.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00
Liabilities	-7.9%	163	177	165	170	170	200	177	174	194	229	237	231	242	250	262	240	216	217	215	218	288
Current Liabilities	-1.2%	98.00	99.00	67.00	60.00	48.00	77.00	60.00	57.00	75.00	110	116	138	140	114	118	95.00	90.00	91.00	88.00	92.00	101
Long Term Debt	-16.7%	55.00	66.00	77.00	88.00	99.00	98.00	98.00	98.00	97.00	97.00	97.00	69.00	76.00	84.00	92.00	97.00	96.00	95.00	94.00	93.00	153
LT Debt, Current	33.3%	45.00	34.00	23.00	11.00	-	-	-	-	-	-	-	31.00	23.00	14.00	6.00	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	66.00	77.00	88.00	99.00	98.00	98.00	98.00	97.00	97.00	97.00	69.00	76.00	84.00	92.00	-	-	95.00	-	-	-
Shareholder's Equity	-4.6%	51.00	53.00	39.00	30.00	26.00	22.00	22.00	20.00	7.00	-	-	29.00	16.00	-	-	23.00	9.00	17.00	17.00	22.00	43.00
Retained Earnings	-0.4%	-1,349	-1,345	-1,357	-1,363	-1,365	-1,366	-1,361	-1,360	-1,370	-1,366	-1,370	-1,326	-1,321	-1,337	-1,322	-1,291	-1,294	-1,277	-1,266	-1,249	-1,212
Additional Paid-In Capital	0.2%	1,401	1,399	1,396	1,394	1,391	1,388	1,383	1,381	1,377	1,364	1,360	1,356	1,338	1,332	1,322	1,315	1,304	1,295	1,283	1,271	1,256
Shares Outstanding	1.2%	48.00	48.00	48.00	47.00	47.00	46.00	46.00	44.00	42.00	41.00	41.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	141	-	-	-	112	-	-	-	374	-	-	-	413	-	-	-	428	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.7%	11,200	10,400	10,700	3,257	2,643	7,683	17,259	-13,874	-26,895	-5,435	10,498	-74.00	15,661	-5,635	1,720	16,228	-11,540	1,566	-7,307	44,247	-16,130
Share Based Compensation	-2.3%	2,377	2,432	2,545	2,432	2,838	2,628	2,830	3,220	3,148	4,252	4,282	18,239	5,860	9,473	7,565	10,630	8,907	11,536	12,213	15,440	18,138
Cashflow From Investing	-133.5%	-19,080	-8,170	11,178	-4,683	-17,450	-11,873	7,998	1,997	8,982	4,621	-4,470	-5,731	-5,301	10,823	-2,578	-9,219	34,377	-432	38,972	11,206	-44,583
Cashflow From Financing	-	-	-	-	-	-	2,431	-53.00	-	9,845	-2.00	-31,929	-	-	-9,977	43.00	-	-	-1.00	76.00	-68,224	1,082

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PBYI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 43,766	$ 52,775
Operating costs and expenses:
Cost of sales	10,728	13,218
Selling, general and administrative	21,750	22,486
Research and development	13,587	12,706
Total operating costs and expenses	46,065	48,410
(Loss) income from operations	(2,299)	4,365
Other income (expenses):
Interest income	972	537
Interest expense	(3,359)	(3,312)
Other income (expense)	91	(42)
Total other expenses, net	(2,296)	(2,817)
Net (loss) income before income taxes	(4,595)	1,548
Income tax expense	(220)	(147)
Net (loss) income	$ (4,815)	$ 1,401
Net (loss) income per share of common stock—basic (in dollars per share)	$ (0.1)	$ 0.03
Net (loss) income per share of common stock—diluted (in dollars per share)	$ (0.1)	$ 0.03
Weighted-average shares of common stock outstanding—basic (in shares)	48,189,256	46,636,083
Weighted-average shares of common stock outstanding—diluted (in shares)	48,189,256	47,157,904
Product [Member]
Total revenue	$ 40,279	$ 46,794
Royalty [Member]
Total revenue	$ 3,487	$ 5,981

PBYI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 76,751	$ 84,585
Marketable securities	30,412	11,354
Accounts receivable, net of allowance for credit loss of $990 and $881	24,584	47,837
Inventory	7,100	7,080
Prepaid expenses, current	3,924	4,417
Other assets, current	255	912
Total current assets	143,026	156,185
Lease right-of-use assets, net	7,023	7,792
Property and equipment, net	757	855
Intangible assets, net	58,436	60,871
Restricted cash, long-term	2,091	2,091
Prepaid expenses and other, long-term	2,816	2,734
Total assets	214,149	230,528
Current liabilities:
Accounts payable	8,964	6,889
Accrued expenses, current	37,716	52,721
Post-marketing commitment liability, current	1,205	975
Lease liabilities, current	4,977	4,800
Current portion of long-term debt	45,329	33,997
Total current liabilities	98,191	99,382
Accrued expenses, long-term	121	121
Lease liabilities, long-term	5,738	7,034
Post-marketing commitment liability, long-term	4,426	4,890
Total long-term debt, net	54,691	65,659
Total liabilities	163,167	177,086
Commitments and contingencies (Note 12)
Stockholders’ equity:
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 48,214,663 shares issued and outstanding at March 31, 2024 and 47,646,787 issued and outstanding at December 31, 2023	5	5
Additional paid-in capital	1,400,982	1,398,605
Accumulated other comprehensive loss	(26)	(4)
Accumulated deficit	(1,349,979)	(1,345,164)
Total stockholders’ equity	50,982	53,442
Total liabilities and stockholders’ equity	$ 214,149	$ 230,528

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

CEO	Mr. Alan H. Auerbach
WEBSITE	pumabiotechnology.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Puma Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for Puma Biotechnology Inc? What does PBYI stand for in stocks?

PBYI is the stock ticker symbol of Puma Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Puma Biotechnology Inc (PBYI)?

As of Tue May 07 2024, market cap of Puma Biotechnology Inc is 229.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PBYI stock?

You can check PBYI's fair value in chart for subscribers.

What is the fair value of PBYI stock?

You can check PBYI's fair value in chart for subscribers. The fair value of Puma Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Puma Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PBYI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Puma Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether PBYI is over valued or under valued. Whether Puma Biotechnology Inc is cheap or expensive depends on the assumptions which impact Puma Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBYI.

What is Puma Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, PBYI's PE ratio (Price to Earnings) is 14.89 and Price to Sales (PS) ratio is 1.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBYI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Puma Biotechnology Inc's stock?

In the past 10 years, Puma Biotechnology Inc has provided -0.235 (multiply by 100 for percentage) rate of return.